Questcor Pharmaceuticals (QCOR) provides drugs for the treatment of multiple sclerosis, nephrotic syndrome, and infantile spasms indications.
It primarily offers H.P. Acthar Gel, an injectable drug for the treatment of acute exacerbations of multiple sclerosis in adults; to induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus; and as monotherapy for the treatment of infantile spasms in infants and children under two years of age.
The companys H.P. Acthar Gel also focuses on rheumatology-related conditions, including collagen diseases and rheumatic disorders. In addition, it offers Doral for the treatment of insomnia.
The company sells its Acthar primarily to specialty pharmacies; and Doral to pharmaceutical wholesalers.
Shares have formed another bullish "flag" and higher share prices are expected for this stock.
52-Week Trading Range: $17.25 - $70.55
Entry Point: $67.00
Here is the trade:
Buy One September $67.5 Call for less than $4.30
Sell One September $75 Call for less than $2.05
Net Investment: $2.25
Payoff is shown below.
Trade
Profit/Loss Analysis
Closing Summary
|
|